

## BIBLIOGRAPHY

### EBV: A NEW FACTOR IN THE CARE OF CHRONIC PAIN

1. Aalto SM, Linnavuori K, Peltola, et al. Immunocostivation of Epstein-Barr virus due to cytomegalovirus disease. *J Med Virol* 1998;56:186-91.
2. Aldrete JA. Suspecting and diagnosing arachnoiditis. *Pract Pain Mgt* 2006;16:74-87.
3. Alspaugh MA, Henle G, Lennette E, et al. Elevated levels of antibodies to Epstein-Barr virus antigens in sera and synovial fluids of patients with rheumatoid arthritis. *J Clin Invest* 1981;67:1134-1140.
4. Anderson TL, Morris JM, Wald JT, et al. Imaging appearance of advanced chronic adhesive arachnoiditis: A retrospective review. *Am J Roentgenol* 2017;209:648-655.
5. Andre G, Trompet E, Snoeck R. Novel therapeutics for Epstein-Barr virus. *Molecules* 2019;24:997-1009.
6. Apkarian AV, Sosa Y, Sont S, et al. Chronic back pain is associated with decreased prefrontal and thalamic gray matter density. *J Neurosci* 2004;24:10410-10415.
7. Baken JS. Epstein-Barr-Virus induced glomerulonephritis. *Tidsske Nor Laegeforen* 1980;100:558-560.
8. Bashir K, Lipton RB, Achina S, et al. Migraine and structural changes in the brain. *Neurology* 2013;81:1-9.
9. Bilello J, Tennant F. Patterns of chronic inflammation in extensively treated patients with arachnoiditis and chronic intractable pain. *Postgrad Med* 2016;92:1-5.
10. Binne UK, Amun W, Furrell PJ. Promotor sequence required for reactivation of Epstein-Barr virus from latency. *J Virology* 2002;76:10282-10289.
11. Birkenfeld P, Haratz N, Klein G, et al. Cross reactivity between the BNA-LP107 peptide, collagen, and keratin: implications for the pathogenesis of rheumatoid arthritis. *Clin Immunol & Immunopath* 1990;54:14-25.
12. Bjornevik K, Cortese M, Healy BC, et al, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. *Science* 2022;375:296-301.
13. Bonor RA, Weinstein D, Sommer JR, et al. Virus of avian myeloblastosis XVII morphology of progressive virus myeloblast interactions in vitro. *US Nat Cancer Inst Monog* 1960;4:251-290.
14. Bronz G, Benedetto P, Zanetti SM, et al. Bilateral upper eyelid swelling (Hoagland sign) in Epstein-Barr infectious mononucleosis: prospective experience. *Infection* 2023;51:471-474.
15. Brunell PA, Gershon AA, Uduman SA, et al. Varicella-zoster immunoglobulins during varicella, latency, and zoster. *J Infect Dis* 1975;132:49-54.
16. Buchwald D, Garrity D. Chronic fatigue, fibromyalgia and chemical sensitivity: overlapping disorders. *Arch Intern Med* 1994;154:2049-2053.
17. Buckalew N, Haut MW, Morrow L, et al. Chronic pain is associated with brain volume loss in older adults: preliminary evidence. *Pain Med* 2008;9:240-248.
18. Burkitt DP. Primary hydrocele and its treatment: a review of 200 cases. *Lancet* 1951;1:1341-1343.
19. Burkitt DP. A sarcoma involving the jaws of African children. *Brit J Surg* 1958;46:218-223.
20. Burkitt DP, O'Connor GT. Malignant lymphoma in African children: a clinical syndrome. *Cancer* 1961;14:258-269.
21. Campana WM. Schwann cells: activated peripheral glia and their role in neuropathic pain. *Brain Behav Immun* 2007;21:522-527.

22. Catalano MA, Carson DA, Sloven SF, et al. Antibodies to Epstein-Barr virus-determined antigens in normal subjects and in patients with seropositive rheumatoid arthritis. *Proc Nat Acad Sci* 1979;76:5825-5828.
23. Cauda F, Palerno S, Costa T, et al. Gray matter alterations in chronic pain: a network-oriented meta-analytic approach. *Neuroimage Clin* 2014;16:676-685.
24. Chang DM, Chu SJ, Chen HC, et al. Dehydroepiandrosterone suppresses interleukin 10 synthesis in women with systemic lupus erythematosus. *Ann Rheum Dis* 2004;63:1623-1620.
25. Clark EH, Ashley P, Shandera WX. Epstein-Barr virus & infectious mononucleosis in *Current Medical Diagnosis and Treatment*. Ed Papdakis MA, McPhee JJ, Rabow MW. McQuaid KP. *McGraw Hill*, New York 2024:1371-1373.
26. Cohen JL. Epstein-Barr Virus infection. *New Eng J Med* 2000;343:481-492.
27. Cohen JL, Wang W, Mannick J, et al. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. *Proc Natl Acad Sci USA* 1989;86:9558-9562.
28. Coskum O, Sener K, Kilic S, et al. Stress-related Epstein-Barr virus reactivation. *Clin Exp Med* 2010;10:15-20.
29. Duan Y, et al. Immune cell infiltration and the genes associated with ligamentum flavum hypertrophy: identification and validation. *Front Cell Dev Biol* 2022;10:91478.
30. Eladwy RA, Vu HT, Shah R, et al. The fight against the carcinogenic Epstein-Barr virus: gut microbiota, natural medicines and beyond. *Int J Mol Sci* 2023;24:1716-1725.
31. Epstein MA, Barr YM, Achang BC. Virus particles in cultured lymphocytes from Burkitt's lymphoma. *Lancet* 1964;1:702-703.
32. Fine PG. Long-term consequences of chronic pain: mounting evidence for pain as a neurologic disease and parallels with other chronic disease states. *Pain Med* 2011;12:996-1004.
33. Fischer GA. Studies of the culture of leukemic cells in vitro. *Annals NY Acad Sci* 1958;76:673-680.
34. Gome K, Goldman RD. Corticosteroids for infectious mononucleosis. *Can FAM Physician* 2023;2:101-102.
35. Gordon MP. Corticosteroid treatment of infectious mononucleosis in a military population. *Military Medicine* 1968;133:303-305.
36. Gould GM, Pyle WL. Autoinfection in *Cyclopedia of Practical Medicine and Surgery*. P *Blakiston's Son & Co.*, Philadelphia, 1900.
37. Harley JB, Chan X, Pujato M, et al. Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. *Nat Genet* 2018;50:699-707.
38. Harrow T. Epstein-Barr virus could be a cause of multiple autoimmune disorders. *VA Research Currents* April 18, 2018.
39. Henle G, Henle N, Diehl V. Relation of Burkitt's tumor associated herpes type virus to infectious mononucleosis. *Proc Natl Acad Sci* 1968;59:94-101.
40. Henle G, Henle W. Immunofluorescence in cells derived from Burkitt's lymphomas. *J Bact* 1966;91:1248-1256.
41. Henle G, Henle W, Klein G, et al. Antibodies to early Epstein-Barr virus-induced antigens in Burkitt's lymphoma. *J Nat Cancer Inst* 1971;46:861-871.
42. Henle W, Henle G. Epstein-Barr virus-related serology in Hodgkin's disease. *Nat Cancer Inst Monograph* 1973;36:79-84.
43. Henle G, Henle W, Diehl V. Relation of Burkitt's tumor associated herpes type virus to infectious mononucleosis. *Proc Natl Acad Sci* 1968;59:94-101.

44. Hirshout Y, Glade P, Viera LO, et al. Sarcoidosis, another disease associated with serologic evidence for herpes-like infection. *New Eng J Med* 1970;283:502-506.
45. Hoagland RJ. Infectious mononucleosis. *Amer J Med* 1952;13:158-171.
46. Hoagland RJ, Henson HM. Splenic rupture in infectious mononucleosis. *Ann Intern Med* 1957;46:1184.
47. Houen G, Trier NH. Epstein-Barr virus and systemic autoimmune disease. *Front Immunol* 2020;11:1-13.
48. Hsu D, Malefytro W, Fiorentino DF, et al. Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF 1. *Science* 1990;250:830-832.
49. Hung AL, Lim M, Doshi TC. Targeting cytokines for treatment of neuropathic pain. *Scand J Pain* 2017;17:287- 293.
50. Indari O, Tiwari D, Tanwar M, et al. Early biomolecular changes in brain microvascular endothelial cells under Epstein-Barr virus influence: A Raman microspectroscopic investigation. *Integr Biol* 2022;14:89-97.
51. Indari O, Jakhomola S, Pathak DK, et al. Comparative account of biomolecular changes post Epstein Barr virus infection of the neuronal and glial cells using Raman microspectroscopy. *ACS Chem Neurosci* 2022;13:1627-1637.
52. Jakhmola S, Jha HM. Glial cell response to Epstein Barr Virus infection: a plausible contribution to virus-associated inflammatory reactions in the brain. *Virology* 2021;559:182-195.
53. Jauregui-Huerta F, Ruvalcaba-Delgadillo Y, Gonzales-Casteneda R, et al. Responses of glia cells to stress and glucocorticoids. *Curr Immunol Rev* 2010;6:195-204.
54. Javida E, Magnus T. Autoimmunity after ischemic stroke and brain injury. *Front Immunol* 2019;10:1-12.
55. Jha HC, Pei Y, Robertson ES. Epstein-Barr virus: disease linked to infection and transformation. 2016;7:1-16.
56. Johansson B, Klein G, Henle W, et al. Epstein-Barr virus (EBV) associated antibody patterns in malignant lymphoma and leukemia. I. Hodgkins disease. *Int J Cancer* 1970;6:450-462.
57. Johansson B, Klein G, Henle W, et al. Epstein-Barr virus (EBV) associated antibody patterns in malignant lymphoma and leukemia. II. chronic lymphatic leukemia and lymphocytic lymphoma. *Int J Cancer* 1971;8:475-486.
58. Jones KJ. Gonadal steroids and neuronal regeneration: a therapeutic role. *Adv Neurol* 1993;59:227-240.
59. Katz, BZ. Infectious mononucleosis in *Conn's Current Therapy* 2024, ed. Kellerman RD, Rakel DP, Heidelbaugh JJ, Lee FM. Elsevier Philadelphia, 626-627.
60. Kenney SC, Mertz JE. Regulation of the latent-lytic switch in Epstein-Barr virus. *Semin Cancer Biol* 2014;26:60-68.
61. Kerr J. Epstein Barr Virus (EBV) reactivation and therapeutic inhibitors. *J Clin Pathol* 2019;0:1-8.
62. Kiefer R, Kreutzberg GW. Effects of dexamethasone on microglial activation in vitro. *J Neuroimmunology* 1991;34:99-108.
63. Kiguchi N, et al. Chemokines and cytokines in neuroinflammation leading to neuropathic pain. *Curr Opinion Pharmacol* 2012;12:55-61.
64. Li YL, Wang JY, Lil K, et al. Epstein-Barr virus to be a trigger of autoimmune glial fibrillary acidic protein astrocytopathy. *CNS Neurosci Ther* 2023;29:4139-4146.

65. Libert N, Bigailon C, Chargari C, et al. Epstein-Barr virus reactivation in critically ill immunocompetent patients. *Biomed J* 2015;38:70-76.
66. Lofgren S. Concepts of sarcoidosis. *Pasth Med Scand* 1964;425:1-6.
67. Maier A, Kapfenberger R, Katano I, et al. Nonregional small fiber neuropathy in cases of autoimmune autonomic neuropathy. *J Neurol* 2022;269:6648-6654.
68. Meisel C, Schwab JM, Prass K, et al. Central nervous system injury-induced immune deficiency syndrome. *Nat Rev Neurosci* 2005;6:775-786.
69. Mika J, Zychowska M, Popiolek-Barczy K, et al. Importance of glial activation in neuropathic pain. *Eur J Pharmacol* 2013;716:106-119.
70. Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. *Nat Rev Neurosci* 2009;10:23- 36.
71. Nagata K, Hayashi K. Epstein-Barr virus reactivation-induced immunoglobulin production: significance on autoimmunity. *Microorganisms* 2020;8:1875-1890.
72. Nahmias AJ, Roizman B. Infection with herpes simplex viruses 1 and 2. *N Engl J Med* 1973;289:667-674.
73. Nakamura M, Burasteros F, Vaki Y, et al. Proving the normal and autoimmune B cell repertoire with Epstein-Barr virus, frequency of B cells producing monoreactive high affinity autoantibodies in patients with Hashimoto's disease and systemic lupus erythematosus. *J Immunol* 1998;141:4165-4172.
74. Ngou J, Graafland H, Segondy M. Antibodies against polypeptides of purified Epstein-Barr virus in serum from patients with connective tissue diseases. *J Autoimmun* 1992;5:243-249.
75. Niederman JC, McCollum W, Henle G, et al. Infectious mononucleosis: clinical manifestations in relation to Epstein-Barr virus. *J Am Med Assoc* 1968;203:139-143,
76. O'Callaghan JP, Sriram, Miller DB. Defining "neuroinflammation". *Ann NY Acad Sci* 2008;1139:318-330.
77. Ogra PL, Kerr-Grant D, Umana G, et al. Antibody response in serum and nasopharynx after naturally acquired and vaccine-induced infection with rubella virus. *N Eng J Med* 1971;285:1333-1339.
78. Okano M, Kawa K, Kimura H, et al. Proposed guidelines for diagnosing chronic active Epstein-Barr infection. *Am J Hematol* 2005;80:64-69.
79. Pridgen WL, Duffy C, Gendreau JF, et al. A famciclovir and celecoxib combination treatment is safe and efficacious in the treatment of fibromyalgia. *J Pain Res* 2017;10:451-460.
80. Raffaelli W, Arando E. Pain as a disease: an overview. *J Pain Res* 2017;10:2003-2008.
81. Reddy DS. Neurosteroids: endogenous role in the human brain and therapeutic potentials. *Prog Brain Res* 2010;186:13-137.
82. Rhodes G, Pumpold H, Kurki P, et al. Autoantibodies in infectious mononucleosis have specificity for the glycine-alanine repeating region of the Epstein-Barr virus nuclear antigen. *J Exp Med* 1987;165:1026-1040.
83. Rickinson AB. Chronic symptomatic Epstein-Barr virus infection. *Immunol Today* 1986;7:13-14.
84. Rodriguez-Raecke R, Niemeier A, Ihler K, et al. Brain gray matter decrease in chronic pain is the consequence and not the cause of pain. *J Neurosci* 2009;29:13746-13750.
85. Ross CAC, McDaid R. Specific IgM antibody in serum of patients with herpes zoster infections. *Br Med J* 1972;4:522-523.

86. Seminowicz DA, Labus JS, Bueller JA, et al. Regional gray matter density changes in brains of patients with irritable bowel syndrome. *Gastroenterology* 2010;139:48-57.
87. Seminowicz DA, Wideman TH, Naso L, et al. Effective treatment of chronic low back pain in humans reverses abnormal brain anatomy and function. *J Neuroscience* 2011;31:7540-7550.
88. Soni N, Ora R, Sing P, et al. Unpacking the CNS manifestations of Epstein-Barr virus: an imaging perspective. *Amer J Neurorad* 2023;44:1002-1008.
89. Strannegard O, Holm SE, Hermudson S, et al. Case of apparent reinfection with rubella. *Lancet* 1970;1:240-241.
90. Strauss SE. The chronic mononucleosis syndrome. *J Infect Dis* 1988;157:405-412.
91. Sumaya CV, Henle W, Henle G, et al. Seroepidemiologic study of Epstein-Barr virus infections in a rural community. *J Infect Disease* 1975;131:403-408.
92. Sumaya, CV. Endogenous reactivation of Epstein-Barr virus infection. *J Infect Dis* 1977;135:374-379.
93. Sunderson B, Shirafkan F, Ripperger K, et al. The role of viral infections in the onset of autoimmune diseases. *Viruses* 2023;15:782-814.
94. Sutton RN, Emond RT, Thomas DB, et al. The occurrence of autoantibodies in infectious mononucleosis. *Clin Exp Immunol* 1974;17:427-436.
95. Takahashi H, Sugura T, Okazimo Y, et al. Inflammatory cytokines in the herniated disc of the lumbar spine. *Spine* 1996;21:218-224.
96. Takedo K, Sawamura S, Sekiyama H, et al. Effect of methylprednisolone on neuropathic pain and spinal glial activation in rats. *Anesthesiology* 2004;100:1249-1257.
97. Teitelbaum J. Effective treatment for chronic fatigue syndrome and fibromyalgia: an overview and 35 treatments for tough cases. *Townsend Letter* Nov, 2015:56-59.
98. Teitelbaum JE, Bird B, Greenfield RM, et al. Effective treatment of chronic fatigue syndrome and fibromyalgia-randomized, double-blind, placebo-controlled, intent to study. *J of Chron Fatigue Synd* 2000;8:3-15.
99. Tennant F, Hermann L. Intractable or chronic pain: there is a difference. *West J Med* 2000;173:306.
100. Tennant F. The physiologic effects of pain on the endocrine system. *Pain Ther* 2013;2:75-86.
101. Tennant FS. The glomerulonephritis of infectious mononucleosis. *Texas Rpts Biol Med* 1969;26:603-612.
102. Thompson SJ, Pitcher MH, Stone LS, et al. Chronic neuropathic pain reduces opioid receptor availability with associated anhedonia in rat. *Pain* 2018;159:1856-1866.
103. Thurley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the urging of associated lymphomas. *N Engl J Med* 2004;350:1328-1337.
104. Tiwari D, Mittal N. Unraveling the links between neurodegeneration and Epstein-Barr virus-mediated cell cycle dysregulation. *Curr Res Neurobiol* 2023;3:2665-2945.
105. Tsai YT, Chiang BL, Kao YF, et al. Detection of Epstein-Barr virus and cytomegalovirus genome in white cells from patients with juvenile rheumatoid arthritis and childhood systemic lupus erythematosus. *Intern Arch Allergy Immunol* 1995;106:235-240.
106. Tsuda M, Beggs S, Salter MW, et al. Microglia and intractable chronic pain. *Glia* 2012;61:55-61.
107. Upchurch KS, Jonathan K. Evolution of treatment for rheumatoid arthritis. *Rheumatology* 2012;51:28-36.

108. Vaughn JH. The Epstein-Barr virus in autoimmunity. *Springer Semin Immunopathol* 1995;17:203-230.
109. Wang L, Wang FS, Gershwin ME. Human autoimmune disease: a comprehensive update. *J Intern Med* 2015;278:369-395.
110. Wahren B, Carlen E, Espmark A, et al. Antibodies to various herpes viruses in sera from patients with sarcoidosis. *J Nat Cancer Inst* 1971;47:747-756.
111. Watkins LR, Hutchinson MR, Ledebor H, et al. Glia as the "bad guys": implications for improving clinical pain control and the utility of opioids. *Brain Behav Immun* 2007;21:131-146.
112. Watkins LR, Maier SF. Beyond neurons: evidence that immune and glial cells contribute to pathologic pain states. *Physiol Rev* 2002;82:981-1011.
113. Wood PB, Glabus MF, Simpson R, et al. Changes in gray matter density in fibromyalgia: correlation with dopamine metabolism. *J Pain* 2009;10:609-618.
114. Zang Y, Chee A, Shi P, et al. Intervertebral disc cells produce interleukins found in patients with back pain. *Am J Phys Med* 2016;95:407-415.
115. Zhang N, Zou Y, Jiang L, et al. Epstein Barr virus and neurologic diseases. *Front Mol Biosci* 2022;10:1-34.
116. Zweiman B, Levinson AI. Immunologic aspects of neurological and neuromuscular diseases. *JAMA* 1992;268:2918-2922.